Sees FY25 total revenue guidance of $1.03B to $1.095B, including DAYBUE net sales guidance of $380M to $405M and NUPLAZID net sales guidance of $650M to $690M.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACAD:
Questions or Comments about the article? Write to editor@tipranks.com